Monday, July 21st Nima Farzan, the Executive Vice President and Chief Operating Officer of immunization technology firm PaxVax welcomed Ambassador LeVine to PaxVax’s newly acquired facility near Bern, Switzerland. In spite of the facility’s recent renovation and long and storied history as part of Swiss vaccine technology legend Crucell AG, the facility was facing closure. But thanks to the PaxVax acquisition more than sixty Swiss scientists and employees will keep their jobs advancing immunization technology, while PaxVax assumes manufacturing, sales, and distribution authority related to the FDA-approved oral typhoid vaccine Vivotif.
In addition to Vivotif, the PaxVax portfolio now includes vaccines in clinical development for cholera, anthrax, HIV, and H5N1 (pandemic bird flu) as well as research for malaria, dengue, rabies and HSV. In addition to their newly acquired Bern facility, PaxVax has offices in Redwood City, California and maintains research and development facilities in San Diego, California, USA.